Transmitted antiretroviral drug resistance in New York City, 2006-2010: The first five years of routine genotype surveillance

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 3, 2013, Pages

  Torian, Lucia V ^a   Forgione, Lisa A ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; LETTER; PATIENT CARE; POVERTY; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; UNITED STATES; VIROLOGY; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; NEW YORK CITY; UNITED STATES; YOUNG ADULT;

EID: 84880246656     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828d2fc1     Document Type: Letter

References (13)

1. Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr. 2012;61:258-262.
2. Castor D, Low A, Evering T, et al. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1 infected individuals in New York City. J Acquir Immune Defic Syndr. 2012;61:1-7.
3. Shafer RW, Rhee S-Y, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007; 21:215-223.
4. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic resistance interpretation. Clin Infect Dis. 2006;42:1608-1618.
5. HIV drug resistance database. Available at http://www.hivdb.stanford.edu. Accessed February 1, 2013.
6. Parekh B, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses. 2002;18:295-307.
7. Parekh BS, Danson DL, Hargrove J, et al. Determination of mean recency period for estimation of HIV type 1 incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses. 2011; 27:265-273.
8. Readhead AR, Gordon DE, Wang Z, et al. Transmitted antiretroviral drug resistance in New York State, 2006-2008: results from a new surveillance system. PLoS One. 2012;8:e40533.
9. Bennett DE, Camacho RJ, Kuritzkes DR, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance. 2009 update. PLoS One. 2009;4:e4724.
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2007;15:119-125.
11. Green H, Tilston P, Fearnhill E, et al. The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 2008;49:196-204.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services. Guidelines for the use of anti-retroviral agents in HIV-1 infected adults and adolescents; 2007. Available at http://aidsinfo. nih.gov/ContentFiles/AdultandAdolescent GL000721.pdf. Accessed February 1, 2013.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents; 2012. Available at http://aidsinfo. nih.gov/ContentFiles/AdultandAdolescent GL000721.pdf. Accessed February 1, 2013.